药物股继续跑赢大市 多只未有盈利生物股飙升9%-61%破顶
市场忧虑全球出现第二波新冠肺炎疫情,医药板块近日明显跑赢大市,尤其是多只未有盈利的生物股急涨兼部份股价破顶,其中专注於治疗癌症和自身免疫性疾病新药及生物类似的研发和生产商迈博药业-B(02181.HK)一举升破去年5月上市价1.5%及去年6月所创上市高位1.51元,最高见1.74元,现造1.6元,飙升近62%,一向稀疏薄成交急增至296万股创今年新高。
去年底才上市的康宁杰瑞制药-B(09966.HK)三连扬,今早股价升破2月所创上市高位20.65元,最高见22.45元,报22.4元,续涨14%。康希诺生物-B(06185.HK)连续第五天创上市新高,最高见226元,现造222.4元,续涨13%。上海君实生物医药-B(01877.HK)升破本月初所创上市高位42元,最高见42.95元,现造42.9元,涨9.2%。
华领医药-B(02552.HK)延续上周连日强势,今早股价曾重越牛熊线(5.55元),最高见5.7元,创逾半年高,现造5.36元,续涨20%。
诺诚健华-B(09969.HK)、中国抗体制药-B(03681.HK)及歌礼制药-B(01672.HK)依次升逾3%-7%,今年3月才上市的前者高见16.36元屡创上市新高。
蓝筹中生制药(01177.HK)及药明生物(02269.HK)反覆续升2.3%-4%,前者高见12.3元,後者高见140.7再创上市新高。
恒指及国指分别扭四连跌及两两连跌,今天反覆微弹0.5%,分别报23,922及9,722,成交额561亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.